Phaseline

Companies › Day One Biopharmaceuticals

Day One Biopharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 7 registered trials: 3 Phase 2, 3 Phase 1, 1 Phase 3; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tovorafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 3Low-grade Glioma; Craniopharyngioma, Child; Recurrent Langerhans Cell Histiocytosis; Hairy Cell LeukemiaMay 2027
Emiltatug Ledadotin (Emi-Le)
unclear - code-named drug, mechanism not specified in registry text
–Phase 1Triple Negative Breast CancerFeb 2027
DAY301
PTK7-directed antibody-drug conjugate
PTK7Phase 1Advanced or Metastatic Solid TumorsDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05377996Emiltatug Ledadotin (Emi-Le)Phase 1Triple Negative Breast CancerOncologyFeb 2027
NCT05465174TovorafenibPhase 2Craniopharyngioma, ChildOncologyMar 2027
NCT04775485TovorafenibPhase 2Low-grade GliomaOncologyMay 2027
NCT05566795TovorafenibPhase 3Low-grade GliomaOncologyJun 2027
NCT06752681DAY301Phase 1Advanced or Metastatic Solid TumorsOncologyDec 2027
NCT05828069TovorafenibPhase 2Recurrent Langerhans Cell HistiocytosisOncologySep 2028
NCT06965114TovorafenibPhase 1Hairy Cell LeukemiaOncologyMar 2030

Targets

RAF1 (1) BRAF (1) ARAF (1) PTK7 (1)

Companies with the same targets

Roche Ipsen Novartis Hanmi Pharmaceutical Company Pfizer Erasca Pierre Fabre Medicament Haisco Pharmaceutical Group Bayer Nested Therapeutics

Companies built like this

Nuvalent InxMed (Shanghai) RayzeBio Shanghai Kechow Pharma Pierre Fabre Medicament

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.